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Abstract
Background: In traditional Chinese and Korean medicine, an aqueous extract derived from wood and bark of the
Japanese spice bush Lindera obtusiloba (L.obtusiloba) is applied to treat inflammations and chronic liver diseases
including hepatocellular carcinoma. We previously demonstrated anti-fibrotic effects of L.obtusiloba extract in
hepatic stellate cells. Thus, we here consequently examine anti-neoplastic effects of L.obtusiloba extract on human
hepatocellular carcinoma (HCC) cell lines and the signaling pathways involved.
Methods: Four human HCC cell lines representing diverse stages of differentiation were treated with L.obtusiloba
extract, standardized according to its known suppressive effects on proliferation and TGF-b-expression. Beside
measurement of proliferation, invasion and apoptosis, effects on signal transduction and NF-B-activity were
determined.
Results: L.obtusiloba extract inhibited proliferation and induced apoptosis in all HCC cell lines and provoked a
reduced basal and IGF-1-induced activation of the IGF-1R signaling cascade and a reduced transcriptional NF-B-
activity, particularly in the poorly differentiated SK-Hep1 cells. Pointing to anti-angiogenic effects, L.obtusiloba
extract attenuated the basal and IGF-1-induced expression of hypoxia inducible factor-1a, vascular endothelial
growth factor, peroxisome proliferator-activated receptor-g, cyclooxygenase-2 and inducible nitric oxide synthase.
Conclusions: The traditional application of the extract is confirmed by our experimental data. Due to its potential
to inhibit critical receptor tyrosine kinases involved in HCC progression via the IGF-1 signaling pathway and NF-B,
the standardized L.obtusiloba extract should be further analysed for its active compounds and explored as
(complementary) treatment option for HCC.
Background
Hepatocellular carcinoma (HCC) results from chronic
liver disease and is the most common malignancy of the
liver [1]. Chronic Hepatitis B or C leading to liver cir-
rhosis are major risk factors for the development of
HCC [2]. Even in developing countries less than 40% of
patients have a chance for cure when the tumor is diag-
nosed. In more advanced stages there are only reduced
therapeutic options, since e.g. the use of more aggressive
chemotherapeutic approaches is often limited by signifi-
cant liver dysfunction/cirrhosis. Thus, the median survi-
val in advanced HCC without therapy ranges from 4.2
to 7.9 months or even less [3,4]. Small molecules, target-
ing tumor angiogenesis, apoptosis or specific signal
transduction pathways, have gained growing attention in
cancer therapy. The multikinase inhibitor sorafenib is
currently the only approved drug for the treatment of
HCC, prolonging median survival of advanced HCC
from 7.9 to 10.4 months [4]. But side effects and
upcoming resistances reveal that monotherapies with
* Correspondence: rajan.somasundaram@charite.de
1Department of Gastroenterology, Infectiology and Rheumatology, Charité -
Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30,
12203 Berlin, Germany
Full list of author information is available at the end of the article
Freise et al. BMC Complementary and Alternative Medicine 2011, 11:39
http://www.biomedcentral.com/1472-6882/11/39
© 2011 Freise et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.the kinase inhibitors alone are not sufficient suggesting the
need for combinatory and/or multitargeted therapies [5].
The receptor tyrosine kinase insulin like growth fac-
tor-1 receptor (IGF-1R) and its ligands, IGF-1 and IGF-
2, are essential for cell growth and development [6] but
also in the progression of various types of cancer,
including HCC [7-10]. In addition, IGF-1R signaling
protects cells from apoptosis mainly through the PI3K/
Akt and Ras-Raf-MAPK pathways [11,12]. Activation of
IGF-1R critically impacts HCC angiogenesis by induced
expression of vascular endothelial growth factor (VEGF)
and its transcription factor hypoxia inducible factor
(HIF)-1a [13-15]. Inhibition of IGF-1R, e.g by monoclo-
nal antibodies against IGF-1R, has been shown to block
tumor growth in vitro and in a xenograft model of HCC
and to sensitize cells for anti-tumor treatment, indicat-
ing that IGF-1R is a promising antineoplastic target
[16-18]. A clinical trial targeting IGF-1R inhibition is
currently ongoing in patients with advanced solid
tumors. Preliminary data suggest evidence of clinical
activity and good tolerance [19].
IGF-1R signaling via the PI-3K/AKT-axis also impacts
the nuclear factor-kappaB (NF-B), which is not only
considered a key factor in inflammation but also regu-
lates angiogenesis and as a major characteristic mediates
inhibition of apoptosis [20]. NF-B is spontaneously
activated in HCC cells [21,22] and induces expression of
cyclooxygenase-2 (COX-2) or inducible nitric oxide
synthase (iNOS) which support cell survival and might
contribute to the resistance against exogenously induced
tumor cell apoptosis [23,24].
Traditionally, Oriental medicine makes use of compo-
sitions from or mixtures of different plants to prevent
or to treat cancer and liver diseases [25,26]. Novel mul-
titargeted therapeutics including natural compounds
such as epigallocatechin-3-gallate from green tea have
gained growing attention [27].
In traditional Chinese and Korean medicine prepara-
tions from Lindera obtusiloba (L.obtusiloba) comprise a
good physiological compatibility and are applied to treat
inflammations and to improve blood circulation [28].
Especially in Korean medicine an extract of L.obtusiloba
is used for a long time for the treatment of chronic liver
diseases which includes treatment of HCC the endstage
of chronic liver disease (personal communication, Prof.
Ki Young Kim, Wonkwang University, Korea).
Bioactive components from the leaves of L.obtusiloba
described so far exert cytotoxicity against tumors as
shown with human cancer cell lines from lung (A549),
ovarian cancer (SK-OV-3), skin (SK-MEL-2), the central
nervous system (XF498) or colon (HCT15) with half-
maximum inhibitory concentration (IC50) values ranging
from 3-20 μg/ml of the respective compounds [29,30].
We previously found an aqueous extract from wood and
bark of L.obtusiloba to suppress profibrotic stimuli,
exerting anti-oxidative activity, reduction of the expres-
sion of pro-fibrotic marker proteins and inhibition of
matrix-metalloproteinases in hepatic stellate cells [31].
In addition, this extract displayed anti-inflammatory and
anti-adipogenic activity in 3T3-L1 preadipocytes [32].
However, experimental data from in vitro or in vivo
studies on anti-neoplastic effects of L.obtusiloba extracts
in human HCC as complication of chronic liver disease
were not reported so far. We here used well established
HCC cell lines that represent diverse stages of differen-
tiation and different degrees of invasiveness to examine
direct anti-neoplastic effects of L.obtusiloba extract,
standardized to its antiproliferative and anti-fibrotic
effects, on tumor cells and to get insights into signaling
pathways involved. With a clear focus on aspects affect-
ing angiogenesis and tumor cell invasion, we aimed to
understand mechanisms of action of L.obtusiloba
extract.
Methods
Materials and reagents
Tissue culture plates and polystyrene microtiter for
ELISA as well as for fluorimetric analysis were from
Nunc (Roskilde, Denmark) and Dynex (Chantilly, VA),
respectively. If not stated otherwise, all reagents were
purchased from Merck (Darmstadt, Germany) or Sigma-
Aldrich (Deisenhofen, Germany) and were of the highest
purity available. Cell culture media and solutions were
purchased from Invitrogen (Karlsruhe, Germany) or Bio-
chrom (Berlin, Germany).
Preparation and standardization of L.obtusiloba extract
Freeze-dried extracts of L.obtusiloba were obtained as
described previously [31]. To obtain stock solutions, 10
mg powder was redissolved in 10 ml sterile phosphate-
buffered saline (PBS) at 60°C for 30 min. Aliquots were
stored at -20°C. Freshly prepared working solutions of L.
obtusiloba extract were routinely standardized according
to their anti-fibrotic and anti-inflammatory activity as
previously described [31,32]. Briefly, 100 μg/ml L.obtusi-
loba extract had to reduce proliferation of 3T3-L1 prea-
dipoctyes by 45% and to suppress the autocrine
stimulation of TGF-b expression of hepatic stellate cells
by 50% before to be used in the assays with HCC cells.
Cell culture
The human HCC cell lines HepG2 (ATCC HV-8062),
Hep3B (ATCC HV-8064), Huh-7 (JCRB 0403; Tokio,
Japan) and SK-Hep1 (ATCC HTB-52) cells (Fuchs et al.,
2008) were cultured in a humidified atmosphere at 37°C
and 5% CO2. Standard culture medium consisted of
DMEM with 862 mg/l L-alanyl-L-glutamine, 4.5 g/l glu-
cose, 50 μg/ml streptomycin, 50 units/ml penicillin,
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inactivated fetal bovine serum (FBS). Cell layers were
detached with 0.05% trypsin/0.02% EDTA solution. Cell
morphology in culture was directly examined by inverse
phase contrast microscopy (Zeiss, Oberkochen, Germany).
HCC cell proliferation
HCC cells (5 × 10
3) were seeded into 96-well tissue cul-
ture plates in 100 μl standard culture medium. After 24
h, cells were cell cycle synchronized in 100 μlc u l t u r e
medium containing 0.2% FBS for additional 24 h. Cul-
tures were treated with up to 200 μg/ml L.obtusiloba
extract as indicated for 20 h. Proliferation was deter-
mined by adding 0.5 μCi/well [
3H]-thymidine (GE
Healthcare, Munich, Germany) for 4 h. Cells were fixed
with 10% trichloro acetic acid and the DNA was solubi-
lized with 200 mM NaOH, neutralized with an equal
volume of 800 mM HCl and transferred to glass filter
pads. Radioactive decay was monitored by liquid b-scin-
tillation counting within 1 min (LKB Wallac Turku,
Finland).
Cell invasion assays
50 μlo f3m g / m lM a t r i g e l ™ (BD Biosciences, Heidel-
berg, Germany) diluted in ice cold, serum free DMEM
were used to coat the upper compartments of 24-well
transwell inserts (BD Biosciences; pore size 8 μm) for
16 h at 37°C. 2 × 10
5 cells diluted in 300 μl serum free
medium were seeded into the upper compartments and
L.obtusiloba extract was added at a final concentration
of 100 μg/ml. DMEM containing 10% FBS as stimulat-
ing agent was added to the lower compartment and the
plates were incubated for up to 24 h at 37°C in a humi-
dified atmosphere with 5% CO2. Cells that remained in
the upper compartment were gently removed with a
cotton swab. The inserts were then washed with PBS
and invaded cells on the lower surface of the insert
were fixed for 20 min with 2% glutaraldehyde in PBS
and stained using 0.1% crystal violet in water. The
stained cells on each insert were visualized by light
microscopy and manually counted in three independent
spots per insert.
Apoptosis by caspase 3/7 activity
Apoptosis was quantified fluorimetrically from caspase-
3/7 activity. In brief, 2 × 10
5 HCC cells in standard cul-
ture medium were seeded into 24-well tissue culture
plates. Confluent cell layers were thoroughly washed
with DMEM and subsequently incubated with culture
medium containing 0.2% FBS for 24 h. Cells were then
treated for another 24 h in the presence of 100 μg/ml L.
obtusiloba extract or 100 nM staurosporine and 0.2%
FBS. Apoptosis was determined using the SensoLyte™
Homogenous AFC Caspase-3/7 Assay Kit (AnaSpec, San
Jose, CA) according to the manufactures instructions.
Briefly, cells were lysed in 200 μl lysis buffer for 1 h at
4°C. The clear supernatant obtained after centrifugation at
2,500 × g for 30 min was stored at -80°C until measure-
ment. Caspase 3/7-mediated conversion of the substrate
N-acetyl-Asp-Glu-Val-Asp-7 amino-4 trifluoromethyl
coumarin was monitored fluorometrically using a Spectra-
max Gemini EM microplate reader (lex: 380 nm, lem:
500 nm; Molecular Devices, Sunnyvale, CA).
Western-blot
HCC cells cultured in 6-well tissue culture plates with
125 ng/ml human recombinant IGF-1 (Biomol, Ham-
burg, Germany), 100 μg/ml L.obtusiloba extract and a
combination of both for 48 h were rinsed with ice-cold
PBS and lysed with a lysis-buffer containing 50 mM
Tris-HCl pH 7.4, 2.25 M urea, 1.4% sodium dodecyl sul-
fate, 100 mM dithiothreitol, 2 mM NaVO3,5m MN a F ,
and per 10 ml buffer one tablet of Complete Mini Pro-
tease Inhibitor cocktail (Roche, Penzberg, Germany).
Aliquots of 333 μl lysate were transferred to 0.5 ml reac-
tion tubes and frozen at 80°C. Protein content was
determined using the Nano Orange Protein Assay Kit
(Molecular Devices) according to the manufactures
instructions. From each cell lysate, 25 μgp r o t e i np e r
lane were separated by SDS-PAGE and transferred to
nitrocellulose membranes (Bio-Rad, Munich, Germany)
using a tank blot apparatus (Hoefer, Holliston, MA).
Membranes blocked for 1 h with 5% skim milk powder
in a buffer containing 10 mM Tris, 154 mM NaCl, 0.1%
Tween 20 were incubated over night at 4°C with the fol-
lowing specific primary antibodies with the dilution
given: Akt (1:1,250), COX-2 (1:1,000), Erk1/2 (1:1,000),
iNOS (1:1,500), pAkt (1:1,250), pErk1/2 (1:1,250), Stat3
(1:1,250; Cell Signaling, Beverly, MA), b-Actin
(1:10,000), HIF-1a (1:2,000; Novus Biologicals, Littleton,
CO, USA), IGF-1R (1:1,250), pIGF-1R (1:1,250; Imgenex,
San Diego, CA) and PPARg (1:2,000), pStat3 (1:1,250),
VEGF (1:800; Santa Cruz, Santa Cruz, CA). After wash-
ing, membranes were incubated for 1 h with rabbit or
mouse immunoglobulin G-specific horseradish peroxi-
dase-labeled secondary antibodies (1:2,500; Dako, Ham-
burg, Germany). Bands were detected by enhanced
chemiluminescence (GE Healthcare) using the Lumines-
cent Image Analyser LAS-4000 (Fujifilm, Düsseldorf,
Germany). Band intensities were quantified using Image
J and normalized to the b-actin loading control.
Transient transfection of HCC cells
Transfection of the cells was performed using the elec-
troporation method and a NF-B-luciferase reporter
plasmid as described by Stroh et al. [33,34]. Detached
cells (2 × 10
5) were resuspended in 100 μle l e c t r o p o r a -
tion buffer containing 90 mM phosphate buffer pH 7.2,
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NF-B-luciferase reporter plasmid pNF-B-TA-Luc
(Clontech, Mountain View, CA) were added. In an elec-
troporation cuvette with a gap of 2 mm (Biozym, Hes-
sisch Oldendorf, Germany), cells were subjected to
single square pulses of 400 V for 400 μs( H e p G 2 ,
Hep3B and Huh-7) or 600 V for 400 μs( S K - H e p 1 ) ,
allowed to rest for 1 min, and transferred into pre-
warmed standard culture medium. A total of 1 × 10
5
transfected cells in 1 ml culture medium were seeded
into a 24-well plate. Cell viability as determined by Cal-
cein AM staining [32] was about 85% in conjunction
with a cell transfection efficacy of ~75%.
Assessment of NF-B activation by luciferase assay
Twenty hours after transfection with the NF-B-luciferase
reporter plasmid [33] cells were treated with 10 μg/ml
recombinant human TNFa (Peprotech, Hamburg, Ger-
many), 100 μg/ml L.obtusiloba extract, a combination
of both and 15 nM of the NF-B inhibitor 17-
Dimethylamino-ethylamino-17-demethoxygeldanamycin
(17-DMAG, InvivoGen, San Diego, CA). Cells were
incubated for 24 h, washed twice with PBS, and lysed
in 80 μl of reporter lysis buffer (Promega, Mannheim,
Germany). Protein concentrations were determined
using the Nano Orange Protein Assay Kit. Samples
(20 μl) were transferred into a white 96 well plate
before 60 μl of luciferase substrate were added and
mixed for 5 s. Luciferase activity was measured for
0.5 s using a Mithras LB 940 luminescence reader (Bert-
hold Technologies, Bad Wildbad, Germany). NF-B
activity was estimated as relative luminescence units
(RLU) corresponding to equal protein amounts.
Statistical Analysis
One way ANOVA/Tukey Tests were performed using
SigmaStat for Windows (version 2.03; Systat, San Jose,
CA). P < 0.05 was considered significantly different.
Results
L.obtusiloba extract reduces proliferation, induces
apoptosis and blocks invasion of HCC cells
Effects of L.obtusiloba extract on the proliferation of
human HCC cells were tested in cell-cycle synchronized
cell lines. To define effective dose ranges, HCC cells in
culture were treated with up to 200 μg/ml L.obtusiloba
extract (Figure 1A). The range of concentration of
L.obtusiloba extract and the experimental protocols
were adapted from preceding studies dealing with the
extract [31,32].
L.obtusiloba extract reduced the proliferation of all four
human HCC cell lines in a dose-dependent manner. The
IC50 values for the inhibition of the de novo DNA synth-
esis were approximately 100 μg/ml L.obtusiloba extract
for all HCC cell lines. This concentration was used in all
subsequent experiments. Induction of apoptosis due to
exposure of cells with L.obtusiloba extract was deter-
mined by the enzymatic activity of pro-apoptotic cas-
pase-3/-7 (Figure 1B). As shown for the apoptosis inducer
and kinase inhibitor staurosporine used as control, all cell
lines were highly susceptible to induction of apoptosis by
L.obtusiloba extract as shown by 2.2- to 20-fold enhanced
caspase activity. In the differentiated HCC cell lines
HepG2, Hep3B and Huh-7, this effect of L.obtusiloba
extract did not exceed 60% of the effect of 100 nM staur-
osporine. In contrast, L.obtusiloba extract provoked a cas-
pase activity that corresponded to ~80% of apoptosis
induced by staurosporine in the poorly differentiated SK-
Hep1 cells (P < 0.001). Since their migratory potential
mainly defines their aggressiveness, 100 mg/ml L.obtusi-
loba extract was applied to HCC cells in matrigel invasion
assays. Again, while L.obtusiloba extract only slightly atte-
nuated the invasion of HepG2, Huh-7 (P < 0.05) and
Hep3B cells through a reconstituted basement membrane,
it led to a stronger reduction of invasion in SK-Hep1 cells
by 55% (P < 0.01) (Figure 1C). As for direct effects of
L.obtusiloba extract on tumor cells, it diminished the inva-
sive potential of HCC cell lines and was most effective on
cells displaying a highly aggressive phenotype.
L.obtusiloba extract reduces basal and IGF-1-induced
protein expression of VEGF and its transcription factor
HIF-1a
HCC represents a highly vascularized tumor entity and the
tumor cells contribute to that process by production of
proteins regulating angiogenesis. Thus, we next investi-
gated whether L.obtusiloba extract impacts the expression
of VEGF and HIF-1a in HCC cell lines. Linking Huh-7 to
SK-Hep1 cells, stimulation with exogenous IGF-1
enhanced basal expression of VEGF by 1.4- or 3.3-fold,
while in HepG2 and Hep3B no effects of IGF-1 were
observed (Table 1). L.obtusiloba extract alone reduced
VEGF expression in all four cell lines but strongest in
Huh-7 cells. In combination with IGF-1, L.obtusiloba
extract did not affect the IGF-1-induced VEGF expression
in HepG2 cells, but in Hep3B, Huh-7 and SK-Hep1. The
IGF-1-induced enhancement of HIF 1a expression was
most prominent in differentiated HepG2 cells (3.6-fold)
and intermediate in Hep3B (1.5-fold) and SK-Hep1 cells
(1.3-fold). In Huh-7 cells no significant IGF-1-mediated
effects on HIF 1a expression were observed. Similar to
VEGF, L.obtusiloba extract distinctly reduced basal and
IGF-1-induced HIF-1a expression in each of the HCC cell
lines to comparable individual levels that were indepen-
dent of the presence of IGF-1. These findings on VEGF
and HIF-1a pointed to a strong anti-angiogenic potential
of L.obtusiloba extract. Consequently, we studied the
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proteins crucial in neo-angiogenesis.
L.obtusiloba extract decreases the protein expression of
PPARg, COX-2 and iNOS
The expression of the nuclear transcription factor
PPARg and its target genes COX-2 and iNOS are
implicated in hepatocarcinogenesis and in the formation
of enhanced microvessel density in HCC tissues. Effects
of L.obtusiloba extract on the expression of PPARg,
COX-2 and iNOS were examined at protein level (Table 2).
The expression of PPARg in all four HCC cell lines was
enhanced after stimulation with IGF-1. L.obtusiloba
extract reduced both, basal and IGF-1-induced PPARg
Figure 1 Proliferation, apoptosis and invasion of HCC cell lines treated with L.obtusiloba extract. (A) Cell cycle synchronized HepG2,
Hep3B, Huh 7 and SK-Hep1 cells were treated with up to 200 μg/ml L.obtusiloba extract for 24 h. Cultures without L.obtusiloba extract served as
controls. Proliferation was determined by [
3H]-thymidine incorporation within the last 4 h of the culture. Mean values ± SD of three parallel
measurements. (B) HCC cells were incubated with 100 μg/ml L.obtusiloba extract for 24 h. Cultures without additives or with 100 nM
staurosporine served as negative or positive controls, respectively. Enzymatic activities of caspase-3/7 were determined from cell lysates by
fluorogenic substrate conversion. Shown are the mean values ± SD of four parallel measurements. (C) HCC cells were allowed to invade
membranes coated with basement collagen in the absence or presence of 100 μg/ml L.obtusiloba extract. After 24 h, transmigrated cells were
stained with crystal violet and numbers were counted. Shown are the mean values ± SD of three independent experiments with four parallel
measurements.*P < 0.05, **P < 0.01, ***P < 0.001.
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COX-2 was not detected in HepG2 and Huh-7 cells
(Table 2). On the other hand, Hep3B and SK-Hep1
showed a high IGF-1-induced expression of COX-2 by
2.3- and 3.2-fold, respectively and with L.obtusiloba
extract a reduction of both, the basal and the IGF-1-
induced COX-2 expression. Hep3B and Huh 7 cells
showed no expression of iNOS. In HepG2 and SK-Hep1
cells the basal expression of iNOS was enhanced by IGF-
1 by 1.2- and 1.9-fold, respectively. L.obtusiloba extract
reduced the basal and the IGF-1-induced iNOS expres-
sion of both cell lines by ~80%.
Taken together and complementing the results from
the preceding experiments, these data suggest direct
effects of L.obtusiloba extract on the angiogenic pro-
gram of HCC cells via decreased expression of PPARg
and its target genes COX-2 and iNOS thus contributing
to dampened growth and motility of HCC cells.
L.obtusiloba extract blocks expression of VEGF and HIF-1a
via attenuated activation of IGF 1R downstream targets
The IGF-1/IGF-1R axis plays an important role in
angiogenesis and therefore the development of HCC. To
investigate signaling pathways involved, western-blots
specific for (p)IGF-1R and the activation states of its tar-
get proteins were focused on Hep3B as one out of the
three less invasive HCC cells (compare Figure 1C) and
the more aggressive SK-Hep1 cells. In both cell lines
100 μg/ml exogenous IGF-1 increased the phosphoryla-
tion state of the IGF-1R (Figure 2, Table 3). This IGF-1-
mediated activation of the IGF-1R was strongly reduced
i nt h ep r e s e n c eo fL.obtusiloba extract; by half in the
Hep3B and to about a quarter in SK-Hep1 cells. As for
the downstream signaling molecules Akt, Stat3 and Erk,
L.obtusiloba extract did not alter basal phosphorylation.
IGF-1 induced phosphorylation of Akt, Stat3 and Erk
were tested in both cell lines. Increased pAkt levels that
were at least partially abrogated by L.obtusiloba extract
were found to be the most prominent effect. Treatment
with L.obtusiloba extract in combination with IGF-1
markedly decreased the levels of pAkt, pStat3 and pErk
in Hep3B and SK-Hep1 cells.
These findings that L.obtusiloba extract decreased the
basal phosphorylation of Akt, Stat3 and Erk in Hep3B
cells as well as in poorly differentiated SK-Hep1 cells as
a result of reduced stimulatory effects of IGF-1 on its
receptor explains the inhibition of growth and motility
and the induction of apoptosis in HCC cells.
L.obtusiloba extract decreases transcriptional activity of
NF-B
NF-B is a key regulator of crucial pro-inflammatory
cytokines during carcinogenesis and promotes cell survi-
val and angiogenesis. Since L.obtusiloba extract induces
apoptosis (Figure 1B) and displays anti-inflammatory
activity [32], we assessed whether the extract decreases
Table 1 Expression of VEGF and HIF-1a in human HCC cell lines
VEGF expression HIF-1a expression
IGF-1 L.obtusiloba extract IGF-1 and L.obtusiloba extract IGF-1 L.obtusiloba extract IGF-1 and L.obtusiloba extract
HepG2 1.02 ± 0.03 0.75 ± 0.10* 0.93 ± 0.06 3.58 ± 0.26* 0.72 ± 0.07* 0.82 ± 0.11
#
Hep3B 0.82 ± 0.18 0.67 ± 0.09* 0.54 ± 0.10*,
# 1.52 ± 0.21* 0.62 ± 0.11* 0.63 ± 0.07*,
#
Huh-7 1.38 ± 0.05* 0.28 ± 0.10* 0.47 ± 0.08*,
# 0.89 ± 0.12 0.14 ± 0.04* 0.05 ± 0.03*,
#
SK-Hep1 3.28 ± 0.24* 0.93 ± 0.10 0.83 ± 0.09
# 1.28 ± 0.13* 0.67 ± 0.09* 0.68 ± 0.12*,
#
Whole cell lysates from cells treated with 100 μg/ml L.obtusiloba extract, 125 ng/ml human IGF-1 or a combination of both for 48 h and from untreated cells as
control were analyzed by western-blot specific for VEGF and HIF-1a. b-Actin was stained for equal loading control and specific band intensities were normalized
to b-actin. VEGF and HIF-1a protein expression levels were calculated in relation to the respective untreated cells. Mean values ± SD from three independent
experiments. *P < 0.05 compared to the untreated control,
# P < 0.05 compared to IGF-1-treated cells.
Table 2 Expression of PPARg, COX-2 and iNOS in human HCC cell lines
PPARg expression COX-2 expression iNOS expression
IGF-1 L.
obtusiloba
extract
IGF-1 and L.
obtusiloba
extract
IGF-1 L.obtusiloba
extract
IGF-1 and L.
obtusiloba
extract
IGF-1 L.
obtusiloba
extract
IGF-1 and L.
obtusiloba
extract
HepG2 4.31 ± 0.51* 0.76 ± 0.14 1.15 ± 0.09
# n.d. n.d. n.d. 1.17 ± 0.07 0.21 ± 0.14* 0.21 ± 0.09*;
#
Hep3B 1.33 ± 0.12* 0.84 ± 0.09 0.81 ± 0.05
# 2.28 ± 0.19* 0.77 ± 0.08* 1.09 ± 0.04*;
# n.d. n.d. n.d.
Huh-7 1.17 ± 0.05 0.21 ± 0.10* 0.31 ± 0.12*;
# n.d. n.d. n.d. n.d. n.d. n.d.
SK-
Hep1
1.43 ± 0.11* 0.75 ± 0.09* 0.89 ± 0.07
# 3.21 ± 0.34* 0.80 ± 0.07* 0.82 ± 0.09
# 1.87 ± 0.12* 0.27 ± 0.12* 0.35 ± 0.06*;
#
Cell lysates of HCC cell lines as described for Table 1, were subjected to specific western-blots for PPARg, COX 2 and iNOS and for b actin as equal loading
control. Densitometry of specific band intensity was normalized to b-actin expression. Mean values ± SD from three independent experiments. PPARg, COX-2 and
iNOS protein expression levels were calculated in relation to the respective untreated cells. Mean values ± SD from three independent experiments. *P < 0.05
compared to the untreated control,
# P < 0.05 compared to IGF-1-treated cells, n.d. - not detected.
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HCC cell lines transfected for transient constitutive
expression of NF-B exhibited high levels of basal NF-
B transcriptional activity of about 160 260 RLU. This
activity was not significantly increased by addition of
TNFa. In all cell lines, treatment of transfected cells
with the specific NF-B-inhibitor 17-DMAG reduced
the activity to <10% of the basal level thus approving
the function of the experimental system (data not
shown). Except for HepG2 cells, L.obtusiloba extract
attenuated the transcriptional activity of NF-Bt o7 5 %
(P < 0.05) of the basal level in Huh-7 and to ~65% (P <
0.001) in Hep3B cells while in the poorly differentiated
SK-Hep1 cells the high basal transcriptional activity of
NF-B was reduced to 50% (P < 0.001). These results at
the level of regulation clearly strengthen our conclusion
that L.obtusiloba extract directly impairs the survival
and the angiogenic program in HCC cells.
Discussion
In the present study with human HCC cell lines we pro-
vide evidence that a well standardized aqueous extract
Figure 2 Effects of L.obtusiloba extract on the basal and IGF-1-induced IGF-1R signal transduction. As described for Table 2, HCC cells
treated for 24 h with 100 μg/ml L.obtusiloba extract, 125 ng/ml IGF-1, a combination of both or untreated cells were lysed. Whole cell lysates
were analyzed by western-blot with antibodies specific for phosphorylated and normal IGF-1R and its downstream targets Akt and Stat3. Bands
were visualized by chemiluminescence. Blots are representative for three independent experiments. Quantification of the protein-activation (n-
fold to control values) were taken from table 3.
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non-direct anti-neoplastic effects via attenuated IGF-1R-
and NF-B-signaling.
Initially, we examined the effects of a standardized
active extract of L.obtusiloba on the proliferation of well
characterized human HCC cell lines with poorly differ-
entiated SK-Hep1 considered more aggressive than the
other three used. L.obtusiloba extract blocked the
growth of the HCC cells in a dose dependent manner
with a physiologically relevant IC50 of ~100 μg/ml (Fig-
ure 1A) [31,32]. In addition, L.obtusiloba extract inhib-
ited tumor cell invasion (Figure 1C). Here, SK-Hep1
cells rather than the well differentiated HepG2, Hep3B
and Huh-7 cells were more sensitive to L.obtusiloba
extract. Thus, in conjunction with the induction of
apoptosis in all four cell lines (Figure 1B), L.obtusiloba
extract exerts three primary prerequisites for the treat-
ment of cancer [35,36].
Aberrant growth and apoptosis regulation in carcino-
genesis is mediated by growth factor receptors such as
IGF-1R which therefore represents an attractive thera-
peutic target [8,37] and all of the four cell lines investi-
gated are known to express the IGF-1R [38]. Since HCC
is characterized by strong neo-angiogenesis [39] with
VEGF as its main mediator we investigated the
upstream IGF-1/IGF-1R signal transduction and the
expression of VEGF via induction of HIF-1a [13]. L.
obtusiloba extract blocked the basal and IGF-1-induced
protein expression of HIF-1a and VEGF accompanied
by decreased phosphorylation of Akt, Stat3 and Erk.
(Figure 2, Tables 1, 2, 3). Since a forced activation of
Akt, Stat3 and Erk was shown to protect from apoptosis
and to induce VEGF expression [40,41], our results sug-
gest that a decreased activation of the IGF-1/IGF-1R-
axis due to L.obtusiloba extract treatment contributes to
its apoptosis-inducing effects and might be a reason for
the reduced expression of VEGF and HIF-1a in HCC
cells treated with L.obtusiloba extract [11,12]. These
findings are in accordance with studies using extracts
from green tea describing a decreased expression of
Table 3 Effects of L.obtusiloba extract on basal and IGF-1-induced signal transduction via IGF-1R
Hep3B SK-Hep1
IGF-1 L.obtusiloba
extract
IGF-1 and L.obtusiloba
extract
IGF-1 L.obtusiloba
extract
IGF-1 and L.obtusiloba
extract
pIGF-1R 4.81 ± 0.40* 0.73 ± 0.08* 2.21 ± 0.31*; # 22.3 ± 1.98* 0.81 ± 0.07 5.02 ± 0.60*; #
pAkt 2.96 ± 0.25* 1.02 ± 0.10 1.67 ± 0.19*; # 27.7 ± 2.84* 1.12 ± 0.09 19.3 ± 1.45*; #
pStat3 2.01 ± 0.18* 0.20 ± 0.07* 0.38 ± 0.21*; # 2.91 ± 0.22* 1.23 ± 0.20 1.18 ± 0.19#
pErk2 1.32 ± 0.14* 0.13 ± 0.03* 0.57 ± 0.07*; # 2.81 ± 0.32* 1.01 ± 0.10 1.82 ± 0.17*; #
HCC cells were treated with 100 μg/ml L.obtusiloba extract, 125 ng/ml IGF 1, a combination of both or remained untreated for 24 h. Phosphorylation of IGF-1R
and its downstream targets Akt, Stat3 and Erk were studied in whole cell lysates by specific western-blot analysis as shown in representative blots in Fig. 3.
Activation of the proteins was determined from densitometric assessment in comparison to total expression levels of the respective non-phosphorylated protein.
Mean values ± SD in relation to untreated cells from three independent experiments. *P < 0.05 compared to the untreated control,
# P < 0.05 compared to IGF-
1-treated cells.
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Figure 3 NF-B activity of HCC cell lines in the presence of L.obtusiloba extract. HCC cell lines were transfected with a NF-B/luciferase
reporter plasmid and allowed to adhere for 20 h before being treated with 10 μg/ml TNFa, 100 μg/ml L.obtusiloba extract or a combination of
both. Untreated cells served as negative controls. After additional 24 h, cells were lysed and luciferase activity was determined. Shown are the
mean values ± SD of four parallel measurements. *P < 0.05, ***P < 0.001.
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Akt-signaling in HCC cells [42].
IGF-1R signaling also impacts the expression of the
transcription factor PPARg which in turn modulates the
expression of other angiogenesis-regulating proteins like
COX-2 and iNOS. The implication of PPARg in carcino-
genesis is still debated. Some data show anti-tumor
effects of PPARg ligands. However, these effects could
also be independent of PPARg activation and in addition
the usage of PPARg antagonists also exerts anticancer
effects [43]. In contrast to PPARg, several studies clearly
show a positive correlation between the expression of
COX-2 and iNOS and HCC progression, e.g. indicated
as enhanced microvessel density in HCC [44]. While
COX-2 impacts growth and progression of HCC and its
inhibition suppressed HCC-associated angiogenesis in
vitro and in vivo [45], iNOS is a key enzyme in generat-
ing nitric oxide, thus modulating tumorigenesis by regu-
lating tumor cell proliferation, survival and migration, as
well as angiogenesis, drug resistance and DNA repair
[5,46].
In line with previous reports [47,48], L.obtusiloba
extract reduced the expression of COX-2 and iNOS
(Table 2). Notably, poorly differentiated SK-Hep1 cells
were susceptible to IGF-1 and inhibition of IGF-1 by L.
obtusiloba extract. A similar result was obtained for the
expression of PPARg (Table 2). We therefore conclude
that downregulation of COX 2 and iNOS by L.obtusi-
loba extract is mediated by diminished expression of
PPARg.
Beside PPARg, IGF-R-signaling, through different
upstream pathways, could trigger the activation of the
transcription factor NF-B [49] which likewise regulates
COX-2 and iNOS and plays a role in viral hepatitis,
chronic liver disease including fibrosis and cirrhosis and
in HCC [24,50] and is spontaneously activated in HCC
cells [22]. Inhibition of NF-B reduced proliferation and
invasion as well as expression of VEGF in HCC cells
and sensitized the cells to sorafenib induced cell death
[51].
A ss h o w ni nF i g u r e3 ,L.obtusiloba extract markedly
reduced the transcriptional activity of NF-B in Hep3B,
H u h - 7a n dS K - H e p 1c e l l sa n dt oal e s s e re x t e n ti n
HepG2 cells. Thus, downregulation of COX-2 and iNOS
by L.obtusiloba extract is mediated by diminished
expression of PPARg and due to a reduced transcrip-
tional activity of NF-B. Since NF-B activity supports
cell survival or entails anti-apoptotic effects [23,24,49],
the inhibition of NF-Bb yL.obtusiloba extract might
contribute to the apoptosis inducing effects of the
extract in the cancer cells (Figure 1B).
In summary, our findings in vitro strongly suggest L.
obtusiloba extract as a specific compound to suppress
tumor cell growth and migration and to induce
apoptosis in aggressive, poorly differentiated human
tumor cells via attenuation of NF-B transcriptional
activity and IGF-1R signaling. Further, the expression of
key proteins in regulation of angiogenesis was reduced
due to L.obtusiloba extract treatment. Due to its good
physiological compatibility, in Korea L.obtusiloba extract
is traditionally applied in humans to treat chronic
inflammatory diseases of the liver [28]. Thus, our in
vitro results are in line with and add more scientific
strength to the traditional use of L.obtusiloba extract in
treatment for chronic liver disease including HCC.
Regarding biologically active compounds in the extract
several studies describe the isolation and structural char-
acterization of drugs from Lindera obtusiloba [29,30,52].
In this line, preliminary data of us suggest that lignans
such as sesamin or episesamin might contribute to the
anti-fibrotic and anti-tumor effects of L.obtusiloba
extract (not shown).
Complemental to the anti-fibrogenic, anti-inflamma-
tory and anti-adipogenic efficacy of L.obtusiloba extract
[31,32], our results suggest the use of an inflammation-
associated tumor model of HCC to assess all aspects of
the anti-tumor effects of L.obtusiloba extract in vivo.
Conclusions
Due to its potential to inhibit critical receptor tyrosine
kinases involved in HCC progression via the IGF-1 sig-
naling pathway and NF-B, we conclude that L.obtusi-
loba extract or its active compounds represent a useful
tool in a rational complementary approach e.g. with sor-
afenib for treatment of HCC or as cancer preventive
agents.
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